Harpoon Therapeutics and Ambrx Biopharma skyrocket following respective acquisition agreements Check out this morning's top movers from around Wall Street, compiled by The Fly.
HIGHER -
- Harpoon Therapeutics (HARP) up 110% after announcing Merck (MRK), through a subsidiary, will acquire the company for $23.00 per share in cash for an approximate total equity value of $680M
- Ambrx Biopharma (AMAM) up 99% after Johnson & Johnson (JNJ) announced it has entered into a definitive agreement to acquire the company in an all-cash merger transaction for a total equity value of approximately $2B, or $1.9B net of estimated cash acquired
- Axonics (AXNX) up 20% after announcing an agreement to be acquired by Boston Scientific (BSX) for $71 in cash per share, representing an equity value of approximately $3.7B
- American Eagle (AEO) up 8% after reporting that fourth quarter-to-date revenue, through Saturday, December 30, 2023, is up approximately 8%, with American Eagle tracking up high single digits and Aerie up in the low teens
UP AFTER EARNINGS/GUIDANCE -
DOWN AFTER EARNINGS/GUIDANCE -
LOWER -
- Spirit AeroSystems (SPR) and Boeing (BA) down 13% and 7%, respectively, after Reuters reported Spirit manufactured and initially installed the fuselage part on a Boeing 737 Max 9 jet that suffered a blowout on Friday, but Boeing also has a key role in the usual completion process
- Staar Surgical (STAA) down 4% after providing preliminary Q4, FY23 and FY24 guidance
- Alaska Air (ALK) down 5% after temporarily grounding its fleet of 65 Boeing 737-9 aircraft after an incident in which a panel blew off a jet mid flight
- Lululemon (LULU) down 1% after raising its Q4 EPS and revenue outlook
Symbols:
HARP AMAM AEO CROX GCO NVCR STAA LULU - $491.15 /
-4.825 (-0.97%)
ALK MRK JNJ AXNX BSX Keywords: Fly Intel, Wall Street, Top Stories, Stocks